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Background
The immunogenicity of current human immunodefi-
ciency virus-1 (HIV-1) canarypox vaccines is weak and
needs to be improved. Ligation of OX40 (CD134), a
member of tumor necrosis factor receptor superfamily
(TNFRSF), by its ligand OX40L (CD252), a tumor necro-
sis factor superfamily (TNFSF) molecule, has been dem-
onstrated to provide a pivotal costimulatory signal to
enhance CD4 T cell help of humoral and cytotoxic T cell
immune responses. The present study examined whether
an OX40L expressing vector could boost the immuno-
genicity of the HIV-1 canarypox vaccine, vCP1452, in
mice.
Methods
Female Balb/c mice were vaccinated 3 times with 2-week
intervals according to the following schedule: group 1:
naive unimmunized mice; group 2: 10 pfu of vCP1452 +
10 pfu empty vector ALVAC II; group 3: 10 pfu of
vCP1452 + 10 pfu vCPmOX40L; group 4: 10 pfu of
vCP1452 + 5 × 10 pfu vCPmOX40L + 5 × 10 pfu
vCPmCD40L. Six weeks after the last immunization, mice
were sacrificed and spleens and sera were collected for
immunological analysis, including IFN-γ ELISPOT,
tetramer staining, ICS, CFSE proliferation assay, and anti-
Gag ELISA.
Results
Co-immunization of mice with OX40L-expressing canary-
pox and vCP1452 augmented HIV-1 specific CD8 T cell
responses in terms of frequency and cytokine expression.
OX40L-expressing canarypox enhanced the frequency of
antigen specific CD8 T cells with an effector (CD127
CD62L) phenotype, which was associated with an ex vivo
expansion of HIV-1 specific CD4 T cells. Surprisingly,
OX40L did not enhance antibody responses elicited by
the HIV-1 canarypox vaccine. We saw no added benefit by
combining OX40L and CD40L vectors as an adjuvant
strategy for vCP1452.
Conclusion
Our results indicate that, similar to CD40L, OX40L can
enhance the cellular but not humoral immunogenicity of
HIV-1 canarypox vaccines. In summary, our findings
show that OX40L can be used as a molecular adjuvant to
enhance T cell immune responses.
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